AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30975379
Drug: placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo supplement and exercise
Trial: 30975379
Drug: high DHA
RxNorm normalized name: Fish Oil/Stevia Extract 850 MG-10 MG Oral Packet [COROMEGA CHILD BRAIN & BODY HIGH DHA OMEGA-3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high DHA multi-nutrient supplement
Trial: 30975379
Drug: placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo supplement
Trial: 27935924
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of nicotine replacement therapies
Trial: 18259090
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin
Trial: 16181824
Drug: Milrinone, dobutamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone, dobutamine, nitroglycerin, nitroprusside, nesiritide (established drugs approved by the FDA)
Trial: 22658895
Drug: Molar insulin-to-C-peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molar insulin-to-C-peptide ratio (I/C) > 0.175
Trial: 22658895
Drug: Metformin and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and/or thiazolidinedione usage
Trial: 19407666
Drug: Placebo (placebo/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo/placebo and placebo/L-methionine)
Trial: 18085911
Drug: Community residential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community residential treatment (n=139)
Trial: 18085911
Drug: Treatment beyond
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment beyond the index stay
Trial: 11781675
Drug: Sterol esters
RxNorm normalized name: lanosterol esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterol esters (2.4 g)
Trial: 11781675
Drug: Stanols (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanols (2.4 g)
Trial: 9476087
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.05 mg/day) and norethisterone acetate orally (2.5 mg/day) for 12 days every 2 months (group A)
Trial: 9476087
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.05 mg/day) and norethisterone acetate orally (2.5 mg/day) for 12 days every 3 months (group B)
Trial: 24919385
Drug: Meclizine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclizine (25 mg)
Trial: 24346808
Drug: Promethazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (25 mg) plus D-Amphetamine (10 mg)
Trial: 7004560
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent chlorambucil
Trial: 7004560
Drug: Five-drug combination
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug combination (chlorambucil, methotrexate, fluorouracil, vincristine, adriamycin)
Trial: 30730274
Drug: Birch pollen
RxNorm normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch pollen allergoid subcutaneous immunotherapy (4 weekly injections)
Trial: 30730274
Drug: Birch pollen
RxNorm normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch pollen allergoid subcutaneous immunotherapy (7 weekly injections)
Trial: 28671856
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg intravenously every 2 weeks
Trial: 28073844
Drug: Dacarbazine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine 1,000 mg/m2 intravenously every 3 weeks
Trial: 26060154
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (20 minutes, twice a day for four days)
Trial: 17551378
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment consisting of scaling/root planing and oral hygiene instruction
Trial: 17142410
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.5% bupivacaine into the iliac crest harvest site
Trial: 17142410
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received morphine sulfate via patient-controlled analgesia pump
Trial: 14512038
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements (352 kcal/day)
Trial: 10658936
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (8 mg/kg)
Trial: 10658936
Drug: N(G)-monomethyl-L-arginine (L-NMMA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine (L-NMMA; 3 mg/kg) after CsA
Trial: 21270268
Drug: N(G)-monomethyl-L-arginine (L-NMMA)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine (L-NMMA)
Trial: 7551612
Drug: Daily live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily live self-exposure and ritual prevention to external cues (Ex)
Trial: 7551612
Drug: Daily self-exposure
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-exposure to imagined internal cues of the consequences of not ritualising (Exi)
Trial: 8873695
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nicardipine
Trial: 3004113
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg captopril
Trial: 19632949
Drug: S-1 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (oral fluoropyrimidine)
Trial: 18060441
Drug: ramelteon 16
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ramelteon 16 mg
Trial: 10587552
Drug: Calcitriol -
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol - 0.5 microg daily
Trial: 28067086
Drug: Prophylactic dose
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dose of 600 mg of clindamycin, continued with clindamycin postoperatively
Trial: 28067086
Drug: Prophylactic chlorhexidin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic chlorhexidin rinsing, continued randomized amoxicillin clavulanate or clindamycin postoperatively
Trial: 25725179
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose methylprednisolone infusion (1mg/kg loading dose followed by 2mg/Kg/24 hours for 1 day)
Trial: 15142155
Drug: lidocaine‐prilocaine solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine‐prilocaine solution
Trial: 15142155
Drug: inert cream
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert cream
Trial: 11300448
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral estradiol for three months
Trial: 24158593
Drug: Fosdevirine 200
RxNorm normalized name: Fosdevirine
DrugBank: Fosdevirine (DB06166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosdevirine 200 mg
Trial: 24158593
Drug: Control (Etravirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Etravirine 200 mg twice daily)
Trial: 14700098
Drug: BSS with
RxNorm normalized name: BSS Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSS with antibiotics (vancomycin and gentamycin)
Trial: 11053334
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg)
Trial: 1555950
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam irradiation to a dose of 2000 cGy delivered in 10 fractions over 2 weeks (Group A)
Trial: 1555950
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate intracavitary irradiation to a dose of 1200 cGy delivered in two sessions of 600 cGy each a week apart (Group B)
Trial: 21863028
Drug: Focal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal therapy
Trial: 10458683
Drug: Radical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical treatment
Trial: 16724990
Drug: HAI alternating
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI alternating with systemic chemotherapy (HA + SC group)
Trial: 9559492
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) (50.0 mg/ml for 5 minutes)
Trial: 9559492
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mitomycin C (MMC) (0.5 mg/ml for 3.5 minutes)
Trial: 7871085
Drug: Scopolamine (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.3, 0.6 mg IM)
Trial: 17283283
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg oral)
Trial: 7871085
Drug: Scopolamine and
RxNorm normalized name: butylscopolamine and analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine and Lorazepam (active treatments)
Trial: 3281516
Drug: Naftidrofuryl (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (400 mg, two times daily for eight weeks)
Trial: 3281516
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two identical tablets daily for eight weeks)
Trial: 1138025
Drug: DL-methionine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-methionine supplementation at 0.58 g/day
Trial: 11211063
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg)
Trial: 23694974
Drug: NeuroBloc® at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroBloc® at 50 U/ml
Trial: 23694974
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of mean anhidrotic area per unit for 100 U/ml of each product
Trial: 22151935
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied creatine-containing face-care formulation for 6 weeks
Trial: 19192466
Drug: Mirtazapine 30
RxNorm normalized name: mirtazapine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 30 mg at bedtime for 30 days
Trial: 11211743
Drug: Low concentration/high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration/high volume group (LC/HV, 240 ml of total volume and 5 ml.h‐1 of infusion rate, n = 20)
Trial: 11211743
Drug: High concentration/low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration/low volume group (HC/LV, 96 ml of total volume and 2 ml.h‐1 of infusion rate, n = 20)
Trial: 25332252
Drug: Clinical Treatment
RxNorm normalized name: Clinicalm
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clinical Treatment Score (CTS)
Trial: 21118565
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml of green tea
Trial: 12568411
Drug: No Hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Hormone Replacement Therapy (no HRT)
Trial: 11748515
Drug: Sufentanil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil administered by target‐controlled infusion (target effect‐site concentrations ranging from 0.4 to 4.5 ng/mL)
Trial: 11748515
Drug: Concomitant medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant medications (lorazepam, morphine‐scopolamine, clonidine, or propofol)
Trial: 25370890
Drug: Nutri-jelly (200-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutri-jelly (200-ml box as daily supplement throughout radiotherapy)
Trial: 15498086
Drug: Repaglinide dose
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide dose titration based on post-prandial glucose levels
Trial: 15498086
Drug: Repaglinide dose
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide dose titration based on pre-prandial glucose levels
Trial: 15498086
Drug: Repaglinide dose
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide dose titration based on post-prandial glucose levels in metformin-treated individuals
Trial: 15498086
Drug: Repaglinide dose
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide dose titration based on pre-prandial glucose levels in metformin-treated individuals
Trial: 15498086
Drug: Repaglinide dose
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide dose titration
Trial: 8586785
Drug: Chlorine covers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorine covers generated by bathing hands in a solution of 2% sodium tosylchloramide for 1 min.
Trial: 8586785
Drug: Dechlorinated hands
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dechlorinated hands (bathing in a solution of 0.5% sodium thiosulphate for 15 s).
Trial: 767390
Drug: Active alert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active alert hypnotic induction (riding a bicycle ergometer under load, keeping eyes open, receiving suggestions of alertness)
Trial: 767390
Drug: Traditional relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional relaxation induction (standard eye fixation and relaxation induction of the Stanford Hypnotic Susceptibility Scale, Form B)
Trial: 11146708
Drug: No antipyretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antipyretic treatment (Control)
Trial: 1827106
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg 12-hourly
Trial: 1827106
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg 8-hourly
Trial: 7015934
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens (aminophylline + subcutaneously administered epinephrine or inhaled isoproterenol)
Trial: 31084563
Drug: Photobiomodulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation treatment (RTG)
Trial: 31084563
Drug: Photobiomodulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation treatment (LTG)
Trial: 28679189
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dapoxetine two hours before sexual relations for 3 months (Group A)
Trial: 28679189
Drug: Dynamic rehabilitative
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic rehabilitative treatment (Group B)
Trial: 28679189
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment in association with dynamic rehabilitative behavioural treatment for 3 months (Group C)
Trial: 26505826
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (0.8‐g/kg protein, 70% animal and 30% plant proteins)
Trial: 20920295
Drug: Prolastin-C (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin-C (60 mg/kg by weekly intravenous infusion for 8 weeks)
Trial: 20920295
Drug: Prolastin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin (60 mg/kg by weekly intravenous infusion for 8 weeks)
Trial: 20920295
Drug: Prolastin-C (double-blind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin-C (double-blind treatment phase only)
Trial: 10325828
Drug: Alveolar recruitment
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alveolar recruitment strategy with PEEP 15 cm H2O and tidal volume of 18 ml kg‐1 or peak inspiratory pressure of 40 cm H2O
Trial: 4076329
Drug: Lignocaine 250
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 250 mg orally
Trial: 4076329
Drug: Lignocaine 50
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 50 mg intravenously
Trial: 29577973
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg)
Trial: 26446328
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin per day
Trial: 26446328
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg fesoterodine per day
Trial: 20001977
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion of short acting insulin
Trial: 11834235
Drug: MPA+E(2)C injection
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA+E(2)C injection on Day 5 of the menstrual cycle (control group, n = 41)
Trial: 30275886
Drug: Fenofibrate treatment
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate treatment
Trial: 30021076
Drug: Parenteral epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral epinephrine
Trial: 27064136
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol 3 g orally on days 1, 3, and 5
Trial: 27064136
Drug: Ceftriaxone 250
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 250 mg intramuscularly plus azithromycin 1 g orally as a single dose
Trial: 25403144
Drug: Mentalization-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-Based Treatment in a day hospitalization setting (MBT-DH)
Trial: 25403144
Drug: Mentalization-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-Based Treatment in an intensive outpatient setting (MBT-IOP)
Trial: 21769873
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (100 mg kg(‐1))
Trial: 18509121
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg prucalopride
Trial: 18509121
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg and 4 mg prucalopride
Trial: 24068395
Drug: Radiochemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiochemotherapy with molecular anti-EGFR target therapy
Trial: 19912736
Drug: Shenyi Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyi Capsule combined with gemcitabine plus cisplatin (GP) regimen
Trial: 15247911
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine (PncCV)
Trial: 30488789
Drug: Dalteparin (low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (low-molecular-weight heparin)
Trial: 9296467
Drug: Dalteparin (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (lower dose)
Trial: 9296467
Drug: Dalteparin (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (twice-daily administration)
Trial: 8395472
Drug: 20% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% CHO (L‐CHO) and 60% fat (group 3; 7 subjects)
Trial: 3530305
Drug: Oral lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lamotrigine (240 mg)
Trial: 28726590
Drug: Low-/moderate-dose hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-/moderate-dose hypertonic saline
Trial: 24486426
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (C) (n=76)
Trial: 19728091
Drug: Internet-based gender-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based gender-specific drug prevention program (12 sessions)